Qualicorp Consultoria e Corretora de Seguros S.A.

BOVESPA:QUAL3 Stock Report

Market Cap: R$726.0m

Qualicorp Consultoria e Corretora de Seguros Valuation

Is QUAL3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of QUAL3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: QUAL3 (R$2.64) is trading below our estimate of fair value (R$6.24)

Significantly Below Fair Value: QUAL3 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for QUAL3?

Other financial metrics that can be useful for relative valuation.

QUAL3 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.1x
Enterprise Value/EBITDA-179.4x
PEG Ration/a

Price to Sales Ratio vs Peers

How does QUAL3's PS Ratio compare to its peers?

The above table shows the PS ratio for QUAL3 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1x
ODPV3 Odontoprev
2.8x3.1%R$6.3b
PFRM3 Profarma Distribuidora de Produtos Farmacêuticos
0.1xn/aR$913.5m
VVEO3 CM Hospitalar S/A
0.08x6.7%R$869.5m
HAPV3 Hapvida Participações e Investimentos
0.9x8.1%R$25.6b
QUAL3 Qualicorp Consultoria e Corretora de Seguros
0.4x-3.6%R$726.0m

Price-To-Sales vs Peers: QUAL3 is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (1x).


Price to Earnings Ratio vs Industry

How does QUAL3's PE Ratio compare vs other companies in the South American Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a27.7%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a27.7%
n/an/an/a
No more companies

Price-To-Sales vs Industry: QUAL3 is good value based on its Price-To-Sales Ratio (0.4x) compared to the South American Healthcare industry average (0.8x).


Price to Sales Ratio vs Fair Ratio

What is QUAL3's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

QUAL3 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.4x
Fair PS Ratio0.8x

Price-To-Sales vs Fair Ratio: QUAL3 is good value based on its Price-To-Sales Ratio (0.4x) compared to the estimated Fair Price-To-Sales Ratio (0.8x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst QUAL3 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentR$2.64
R$3.15
+19.3%
27.9%R$5.00R$2.20n/a8
Oct ’25R$2.17
R$3.45
+59.0%
46.4%R$7.00R$2.20n/a8
Sep ’25R$2.27
R$3.59
+58.0%
46.5%R$7.00R$2.20n/a7
Aug ’25R$1.49
R$3.56
+138.7%
47.6%R$7.00R$2.00n/a7
Jul ’25R$1.41
R$3.73
+164.4%
45.3%R$7.00R$2.00n/a7
Jun ’25R$1.64
R$4.04
+146.5%
38.0%R$7.00R$2.00n/a7
May ’25R$1.60
R$3.79
+137.2%
37.9%R$7.00R$2.00n/a9
Apr ’25R$1.84
R$3.88
+111.1%
34.6%R$7.00R$2.50n/a9
Mar ’25R$2.56
R$3.81
+48.7%
33.2%R$7.00R$2.50n/a9
Feb ’25R$2.25
R$4.21
+86.9%
27.6%R$7.00R$3.00n/a9
Jan ’25R$3.40
R$4.65
+36.8%
24.2%R$7.00R$3.00n/a8
Dec ’24R$2.91
R$4.65
+59.8%
24.2%R$7.00R$3.00n/a8
Nov ’24R$2.88
R$4.98
+72.8%
25.5%R$7.00R$3.00R$2.319
Oct ’24R$3.08
R$5.37
+74.2%
22.5%R$7.00R$4.00R$2.179
Sep ’24R$3.52
R$5.18
+47.2%
24.6%R$7.00R$3.50R$2.2710
Aug ’24R$4.29
R$5.20
+21.2%
24.4%R$7.00R$3.50R$1.4910
Jul ’24R$4.84
R$5.01
+3.5%
23.4%R$7.00R$3.50R$1.4110
Jun ’24R$4.69
R$5.01
+6.8%
23.4%R$7.00R$3.50R$1.6410
May ’24R$3.97
R$5.74
+44.6%
42.0%R$12.80R$3.50R$1.6012
Apr ’24R$3.68
R$6.25
+70.0%
40.9%R$12.80R$3.50R$1.8411
Mar ’24R$4.68
R$8.21
+75.4%
30.7%R$12.80R$4.00R$2.5611
Feb ’24R$6.37
R$9.14
+43.5%
31.3%R$15.90R$6.00R$2.2512
Jan ’24R$5.87
R$11.27
+91.9%
30.5%R$19.00R$6.50R$3.4012
Dec ’23R$6.15
R$11.27
+83.2%
30.5%R$19.00R$6.50R$2.9112
Nov ’23R$8.20
R$12.36
+50.7%
26.5%R$19.00R$7.00R$2.8812

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies